Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04077879
Recruitment Status : Suspended (Due to COVID-19)
First Posted : September 4, 2019
Last Update Posted : May 15, 2020
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )

Brief Summary:

The purpose of this study is to evaluate the safety and tolerability of single ascending oral doses of ASP1617 in healthy adult non-Asian and Japanese male and female participants.

This study also evaluate the pharmacokinetics and determine the effect of food on the pharmacokinetics of a single oral dose of ASP1617.


Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: ASP1617 Drug: Placebo Phase 1

Detailed Description:
After a screening period of up to 29 days prior to study drug administration, eligible participants will be residential for a single period of 6 days/5 nights in Part 1: single ascending dose, and 18 days in Part 2 multiple ascending dose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 97 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including an Assessment of a Food Effect
Actual Study Start Date : September 19, 2019
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : September 2020

Arm Intervention/treatment
Experimental: Single ascending dose of ASP1617

This is composed of 5 sequential cohorts (cohorts 1.1 to 1.4). If the data from cohorts 1.1 to 1.4 are not sufficient to characterize safety, tolerability and pharmacokinetics, 1 optional cohort (1.5) may be added.

Participants (6-9 for each cohort, consisting of either only non-Asians in cohorts 1.1 and 1.2; or non-Asians plus Japanese in cohorts 1.3, 1.4 and 1.5) will receive a single dose of ASP1617 under fasting conditions.

Drug: ASP1617
Oral

Placebo Comparator: Single ascending dose of Placebo
Participants (2-3 for each cohort, consisting of either only non-Asians in cohorts 1.1 and 1.2; or non-Asians plus Japanese in cohorts 1.3, 1.4 and 1.5) will receive a single dose of matching placebo under fasting conditions.
Drug: Placebo
Oral

Experimental: Single dose of ASP1617 (Food Effect)
Participants (6 Japanese and 3 non-Asian) will receive a single dose of ASP1617 with a high-fat meal. Dosing of the Food Effect cohort will commence after having established the safety and tolerability of the dose tested in cohort 1.4.
Drug: ASP1617
Oral

Experimental: Multiple ascending dose of ASP1617

This is composed of 3 sequential cohorts (cohorts 2.1 and 2.2). If the data from cohorts 2.1 and 2.2 are not sufficient to characterize safety, tolerability and pharmacokinetics, 1 optional cohort (2.3) may be added.

Participants (9 for each cohort, consisting of only non-Asians in cohort 2.1, or non-Asians plus Japanese in cohorts 2.2 and 2.3) will receive ASP1617 for 14 consecutive days at the same dose level.

Based on safety, tolerability and pharmacokinetic data of Part 1, once daily or twice daily dosing will be selected.

Drug: ASP1617
Oral

Placebo Comparator: Multiple ascending dose of Placebo
Participants (3 for each cohort, consisting of either only non-Asians in cohort 2.1, or non-Asians plus Japanese in cohort 2.2 and 2.3) will receive matching Placebo for 14 consecutive days at the same dose level in cohort 2.1 to 2.3. Cohort 2.3 will be added only if the data from cohorts 2.1 and 2.2 are not sufficient to characterize safety, tolerability and pharmacokinetics.
Drug: Placebo
Oral




Primary Outcome Measures :
  1. Number of participants with adverse events (AEs) in Part 1 [ Time Frame: Up to Day 16 ]

    An AE is any untoward medical occurrence in a subject administered an investigational product (IP) and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IP whether or not considered related to the IP.

    AE is considered "serious" if the investigator or sponsor view any of the following outcomes: Death, life-threatening, persistent or significant disability/incapacity, congenital anomaly or birth defect, hospitalization, or medically important event.

    An AE with onset at any time from first dosing until last scheduled procedure will be classified as a treatment-emergent adverse event (TEAE). A drug-related TEAE is defined as any TEAE with a causal relationship assessed as "yes" by the investigator, or records where the relationship is missing.


  2. Number of participants with laboratory value abnormalities and/or AEs in Part 1 [ Time Frame: Up to Day 16 ]
    Number of participants with potentially clinically significant laboratory values.

  3. Number of participants with vital sign abnormalities and/or AEs in Part 1 [ Time Frame: Up to Day 16 ]
    Number of participants with potentially clinically significant vital sign values.

  4. Number of participants with electrocardiogram (ECG) abnormalities and/or AEs in Part 1 [ Time Frame: Up to Day 16 ]
    Number of participants with potentially clinically significant 12-ECG values.

  5. Number of participants with AEs in Part 2 [ Time Frame: Up to Day 29 ]

    An AE is any untoward medical occurrence in a subject administered an IP and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IP whether or not considered related to the IP.

    AE is considered "serious" if the investigator or sponsor view any of the following outcomes: Death, life-threatening, persistent or significant disability/incapacity, congenital anomaly or birth defect, hospitalization, or medically important event.

    An AE with onset at any time from first dosing until last scheduled procedure will be classified as a TEAE. A drug-related TEAE is defined as any TEAE with a causal relationship assessed as "yes" by the investigator, or records where the relationship is missing.


  6. Number of participants with laboratory value abnormalities and/or AEs in Part 2 [ Time Frame: Up to Day 29 ]
    Number of participants with potentially clinically significant laboratory values.

  7. Number of participants with vital sign abnormalities and /or AEs in Part 2 [ Time Frame: Up to Day 29 ]
    Number of participants with potentially clinically significant vital sign values.

  8. Number of participants with 12-ECG abnormalities and/or AEs in Part 2 [ Time Frame: Up to Day 29 ]
    Number of participants with potentially clinically significant 12-ECG values.


Secondary Outcome Measures :
  1. Part 1: Pharmacokinetics (PK) of ASP1617 in plasma: area under the concentration-time curve (AUC) from the time of dosing extrapolated to time infinity (AUCinf) [ Time Frame: Up to Day 7 ]
    AUCinf will be recorded from the PK plasma samples collected.

  2. Part 1: PK of ASP1617 in plasma: AUC from the time of dosing to the last measurable concentration (AUClast) [ Time Frame: Up to Day 7 ]
    AUClast will be recorded from the PK plasma samples collected.

  3. Part 1: PK of ASP1617 in plasma: maximum concentration (Cmax) [ Time Frame: Up to Day 7 ]
    Cmax will be recorded from the PK plasma samples collected.

  4. Part 2 (first dose): PK of ASP1617 in plasma: AUC from the time of dosing to 24 hours (AUC24) [ Time Frame: Up to 24 hours ]
    AUC24 will be recorded from the PK plasma samples collected. This will be replaced with ACU12 in case of twice daily dosing.

  5. Part 2 (first dose and last dose): PK of ASP1617 in plasma: Cmax [ Time Frame: Up to Day 17 ]
    Cmax will be recorded from the PK plasma samples collected.

  6. Part 2 (last dose): PK of ASP1617 in plasma: AUC during a dosing interval, where tau(τ) is the length of the dosing interval (AUCtau) [ Time Frame: Up to Day 17 ]
    AUCtau will be recorded from the PK plasma samples collected.

  7. Part 2 (last dose): PK of ASP1617 in plasma: accumulation ratio calculated using AUC (Rac(AUC)) [ Time Frame: Up to Day 17 ]
    Rac(AUC) will be recorded from the PK plasma samples collected.

  8. PK of ASP1617 in plasma: concentration immediately prior to dosing at multiple dosing (Ctrough) [ Time Frame: Up to Day 17 ]
    Ctrough will be recorded from the PK plasma samples collected.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • For cohorts that enroll non-Asian subjects, subject does not have East Asian (China, Hong Kong, Macau, Japan, Mongolia, North Korea, South Korea and Taiwan) ancestries.
  • For cohorts that enroll Japanese subjects, subject is first generation Japanese, born in Japan with 4 grandparents of Japanese descent, and must have resided outside of Japan for ≤ 10 years.
  • Subject has a body mass index (BMI) range of 18.5 to 32.0 kg/m2, inclusive and weighs at least 50 kg at screening.
  • Female subject is not pregnant and at least 1 of the following conditions apply:

    • Not a woman of childbearing potential (WOCBP)
    • WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 30 days after final investigational product (IP) administration.
  • Female subject must agree not to breastfeed starting at screening and throughout the study period and for 30 days after final IP administration.
  • Female subject must not donate ova starting at first dose of IP and throughout the study period and for 30 days after final IP administration.
  • Male subject with female partner(s) of child-bearing potential (including breastfeeding partner[s]) must agree to use contraception throughout the treatment period and for 30 days after final IP administration.
  • Male subject must not donate sperm during the treatment period and for 30 days after final IP administration.
  • Male subject with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 30 days after final IP administration.
  • Subject agrees not to participate in another interventional study while participating in the present study.

Exclusion Criteria:

  • Subject has received any investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening.
  • Subject has any condition, which makes the subject unsuitable for study participation.
  • Female subject who has been pregnant within 6 months prior to screening or breastfeeding within 3 months prior to screening.
  • Subject has a known or suspected hypersensitivity to ASP1617 or any components of the formulation used.
  • Subject has had previous exposure with ASP1617.
  • Subject has any of the liver function tests (alkaline phosphatase [ALP], ALT, AST, gamma glutamyl transferase and TBL) above the upper linit of normal (ULN) on day -1. In such a case, the assessment may be repeated once.
  • Subject has creatinine level outside normal limits on day -1. In such a case, the assessment may be repeated once.
  • Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to first IP administration.
  • Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy.
  • Subject has/had febrile illness or symptomatic, viral, bacterial or fungal infection within 1 week prior to day -1.
  • Subject has any clinically significant abnormality following the physical examination, ECG and protocol-defined clinical laboratory tests at screening or on day -1.
  • Subject has a mean pulse < 45 or > 90 bpm; mean systolic blood pressure (SBP)140 mmHg; mean diastolic blood pressure (DBP) > 90 mmHg (measurements taken in triplicate after subject has been resting in the supine position for at least 5 minutes; pulse will be measured automatically) on day -1. If the mean blood pressure exceeds the limits above, 1 additional triplicate may be taken.
  • Subject has a mean QTcF of > 430 msec (for male subjects) and > 450 msec (for female subjects) on day -1. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG may be taken.
  • Subject has used any prescribed or nonprescribed drugs in the 2 weeks prior to first IP administration, except for occasional use of acetaminophen (up to 2 g/day) topical dermatological products, including corticosteroid products, hormonal contraceptives or hormone replacement therapy (HRT).
  • Subject has smoked, used tobacco-containing products and nicotine or nicotine-containing products (e.g., electronic vapes) within 6 months prior to screening.
  • Subject has a history of consuming > 14 units for male subjects or > 7 units for female subjects of alcoholic beverages per week within 6 months prior to screening or has a history of alcoholism or drug/chemical/substance abuse within 2 years prior to screening or the subject tests positive for alcohol at screening or on day -1.
  • Subject has used any drugs of abuse within 3 months prior to day -1 or the subject tests positive for drugs of abuse at screening or on day -1.
  • Subject has used any inducer of metabolism in the 3 months prior to day -1.
  • Subject has had significant blood loss, donated ≥ 1 unit (450 mL) of whole blood or donated plasma within 7 days prior to day -1 and/or received a transfusion of any blood or blood products within 60 days.
  • Subject has a positive serology test for hepatitis A virus (HAV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies or antibodies to human immunodeficiency virus (HIV) type 1 and/or type 2 at screening.
  • Subject is an employee of Astellas, the study-related contract research organizations (CROs) or the clinical unit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04077879


Locations
Layout table for location information
United States, California
California Clinical Trials Medical Group / Parexel
Glendale, California, United States, 91206
Sponsors and Collaborators
Astellas Pharma Global Development, Inc.
Investigators
Layout table for investigator information
Study Director: Senior Director Astellas Pharma Global Development, Inc.
Layout table for additonal information
Responsible Party: Astellas Pharma Global Development, Inc.
ClinicalTrials.gov Identifier: NCT04077879    
Other Study ID Numbers: 1617-CL-1001
First Posted: September 4, 2019    Key Record Dates
Last Update Posted: May 15, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. ):
ASP1617
Food Effect
Pharmacokinetics
Healthy Volunteers